Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk.
Source link
Trending
- Thailand’s political woes threatens fragile recovery
- Investing in Space: One big beautiful windfall
- Why European equity markets may be overlooking trade tariff risks
- European market updates: July 4, 2025
- The world’s first trillionaire could use AI to get there
- Outlook for July 7-11, 2025
- Top five tax changes for the wealthy
- Indian regulator SEBI bars Jane Street from accessing securities market
Chart Master: Sell Morgan Stanley, buy Novo Nordisk?
